Alnylam Pharmaceuticals (ALNY) stock surged 5.28% during intraday trading on Tuesday, reflecting strong positive sentiment from investors.
The significant price movement appears to be driven by multiple analyst firms maintaining bullish ratings on the company. Both Canaccord Genuity and Barclays issued reports today reaffirming their Buy ratings on Alnylam Pharma, with price targets of $429.00 and $527.00 respectively.
These positive analyst actions, highlighting confidence in the company's prospects, likely contributed to the stock's upward momentum during the trading session.